In pharmaceuticals, the pipeline is the valuation. That is why Truist’s decision to raise its price target on Amgen to $380 matters: the call followed positive Phase 3 results for dazodalibep, an experimental treatment being studied in moderate-to-severe systemic Sjögren’s disease.

The development gives investors a more constructive lens through which to view Amgen Inc. (NASDAQ: $AMGN). It does not guarantee that the stock will reach Truist’s target, but it does show how credible late-stage clinical progress can improve the growth argument for a large-cap pharmaceutical company. Truist’s revised target reflects its view that pipeline growth is becoming more important to Amgen’s valuation case.

Why the $380 target matters

A price target is an analyst’s valuation estimate, not a promise and not a forecast with a guaranteed outcome. In this case, Truist raised its target on $AMGN to $380 while citing pipeline growth. The timing is significant because the change followed positive Phase 3 results for dazodalibep in an autoimmune indication.

That sequence offers a straightforward explanation for the revised stance. Clinical development is inherently uncertain, and a medicine in an earlier stage generally carries more unanswered questions than one that has advanced to Phase 3. Positive results at this late stage may therefore make a company’s future revenue opportunity appear more credible, even when important uncertainty remains.

Dazodalibep adds weight to the pipeline narrative

Dazodalibep is an experimental drug, and its Phase 3 trial focused on patients with moderate-to-severe systemic Sjögren’s disease. Sjögren’s is an autoimmune disease, placing the program within a therapeutic area where successful development could broaden Amgen’s pipeline prospects.

The key point is not that the trial automatically changes Amgen’s earnings outlook. The supplied information does not provide efficacy figures, regulatory timelines, or additional analyst commentary, so those conclusions would go beyond the evidence. The more measured interpretation is that positive late-stage data can strengthen the case that a company has additional avenues for future growth beyond its existing portfolio.

Why late-stage progress can influence sentiment

Large pharmaceutical stocks are often assessed on more than current operations. Investors also examine whether the pipeline can support future expansion, replace products as markets evolve, and diversify exposure across treatments and disease areas. Positive Phase 3 data may improve confidence in that longer-term framework because it indicates that an experimental program has progressed through an important development stage.

For $AMGN, the dazodalibep results may serve as a potential catalyst for sentiment around the company and, more broadly, the healthcare sector. But “potential catalyst” is the appropriate framing. The assignment does not establish a change in Amgen’s current share price, nor does it confirm that the broader healthcare market has moved in response.

Truist’s higher $380 target is best read as an expression of valuation conviction tied to pipeline growth. It suggests the analyst believes the market may assign greater value to Amgen’s future prospects following the positive Phase 3 update. Whether that view ultimately proves accurate will depend on developments not provided here, including how the program progresses beyond the reported trial results.

The investor takeaway

Amgen’s case illustrates a familiar pattern in biotechnology and pharmaceuticals: late-stage clinical progress can influence sentiment well before a new medicine becomes an established commercial product. The positive dazodalibep results give Truist a specific reason to raise its target, while the absence of a guaranteed outcome keeps the analysis grounded.

For now, the central fact is clear. Truist lifted its price target on $AMGN to $380, citing pipeline growth after positive Phase 3 results in moderate-to-severe systemic Sjögren’s disease. That is a constructive signal for Amgen’s pipeline narrative, but it remains an analyst view rather than a certain destination for the stock.